Research
Hormonal
NuSH-based therapies, including semaglutide and tirzepatide, are highly effective for the treatment of overweight (BMI >27 kg·m−2 with a health condition) and obesity (BMI >30 kg·m−2), with average weight loss exceeding that achieved with lifestyle modification alone.
Healthcare providers should consider prescribing NuSH-based therapies for patients struggling with overweight and obesity.
StrongSupportsmedium confidence
These medications have been shown to be highly effective for the treatment of overweight (body mass index (BMI) >27 kg·m−2 with a concomitant health condition) and obesity (BMI over 30 kg·m−2), with the average weight loss exceeding what is typically achieved with lifestyle modification alone.
Why this rating
The claim is based on the effectiveness of approved pharmacotherapy for obesity.
Source
Contemporary Treatments for Obesity: Physical Activity in the Context of Antiobesity Medications
John M. Jakicic et al. · Translational Journal of the American College of Sports Medicine · 2024
DOI 10.1249/tjx.0000000000000253
reviewCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Chronic use of NuSH-based therapies may improve weight loss in patients who have not responded optimally or have experienced weight recurrence after metabolic/bariatric surgery.Strong
- Physical activity should be promoted as a foundational component of care for patients receiving NuSH-based treatments for obesity.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →